MCRT Webcast: Myeloma Therapies on the Horizon (BLENREP and CELMoDs)- August 22, 2020

Event Description
Research and approval of drug treatments for myeloma continues to move forward, despite the limitations imposed by the pandemic, increasing options, improving quality of life, and extending life expectancy for patients. It is important for myeloma patients to understand what may be available in the foreseeable future to plan their treatment strategies in the coming years with their physicians and nurses.
Drs. Jesus Berdeja and Sagar Lonial discussed two new classes of drugs for myeloma, one recently approved by the FDA, and one in development on Saturday, August 22, 2020.
Thanks to our Round Table sponsors
Virtual Round Table, August 22, 2020
Myeloma Therapies on the Horizon (BLENREP and CELMoDs)
Schedule & Agenda
Speakers & Moderators

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore. Prior to joining the staff at the Sarah Cannon Research Institute and Tennessee Oncology, Dr. Berdeja held appointments in the Stem Cell and Bone Marrow Transplant Program and the Division of Hematology and Oncology at Loma Linda University in Loma Linda, California. Dr. Berdeja has been certified a Diplomate in internal medicine, medical oncology, and hematology by the American Board of Internal Medicine. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group, the Clinical Trials Myeloma Intergroup Committee, and the Center for International Blood and Marrow Transplant Research Plasma Cell Working Group. An active researcher, Dr. Berdeja has been the principal investigator on a number of funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.

Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org






Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.